GlassScriptPhysician profile
Aparna Shah
NPI 1225008303
$11,445.36
in general payments reported to CMS, 2019-2025
31 companies · $2,407 in 2025
The $2,407 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $405 · 2021: $1,031 · 2022: $1,311 · 2023: $2,026 · 2024: $2,628 · 2025: $2,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,937 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,936.93 |
| Education | $123.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,353.45 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $2,035.42 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,760.55 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $874.37 | 2019-2025 | Xolair |
| Genzyme Corporation | $606.77 | 2023-2025 | |
| Csl Behring | $558.01 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $459.87 | 2022-2025 | Entyvio, Takhzyro, Cuvitru |
| Biocryst US Sales Co., LLC | $388.42 | 2021-2025 | Orladeyo |
| Abbvie INC. | $338.36 | 2022-2025 | Rinvoq |
| Shire North American Group INC | $275.12 | 2019 | |
| Pharming Healthcare, INC. | $226.90 | 2023-2025 | Joenja, Ruconest |
| Pfizer INC. | $192.91 | 2023-2025 | |
| Leo Pharma INC. | $189.85 | 2022-2024 | Adbry |
| Teva Pharmaceuticals USA, INC. | $146.42 | 2019-2021 | |
| Grifols USA, LLC | $146.16 | 2023-2025 | Xembify |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.03 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $114.07 | 2024-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Galderma Laboratories, L.P. | $91.59 | 2024-2025 | Nemluvio |
| Incyte Corporation | $84.15 | 2022 | |
| Horizon Therapeutics Plc | $79.79 | 2019-2021 | |
| Blueprint Medicines Corporation | $49.90 | 2024 | Ayvakit |
| Lilly USA, LLC | $33.50 | 2025 | Ebglyss, Taltz |
| Amgen INC. | $29.90 | 2024 | Actimmune |
| Ionis Pharmaceuticals, INC. | $29.03 | 2025 | Dawnzera |
| Novartis Pharmaceuticals Corporation | $26.17 | 2024 | |
| Merck Sharp & Dohme LLC | $24.89 | 2024 | Gardasil 9, Vaqta, Gardasil |
| Aimmune Therapeutics, INC. | $24.85 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.58 | 2025 | Neffy |
| X4 Pharmaceuticals, INC. | $21.36 | 2025 | Xolremdi |
| Cycle Pharmaceuticals INC | $19.02 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aparna Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.